Table 1 Sample characteristics
From: Impact of adult growth hormone deficiency on daily functioning and well-being
Sample size | Germany | United Kingdom | United States | Total |
|---|---|---|---|---|
(n = 14) | (n = 12) | (n = 13) | (n = 39) | |
Gender; n (%) | ||||
Female | 8 (57) | 6 (50) | 9 (69) | 23 (59) |
Male | 6 (43) | 6 (50) | 4 (31) | 16 (41) |
Ethnicity; n (%) | ||||
Caucasian/White | 3 (21) | 11 (92) | 9 (69) | 23 (59) |
Latino | 0 (0) | 0 (0) | 3 (23) | 3 (8) |
Asian | 1 (7) | 1 (8) | 0 (0) | 2 (5) |
Mixed | 1 (7) | 0 (0) | 0 (0) | 1 (3) |
Other | 0 (0) | 0 (0) | 1 (8) | 1 (3) |
Decline to report | 9 (64) | 0 (0) | 0 (0) | 9 (23) |
Marital Status; n (%) | ||||
Married | 8 (57) | 7 (58) | 7 (54) | 22 (56) |
Single | 2 (14) | 3 (25) | 4 (31) | 9 (23) |
Partnered | 2 (14) | 1 (8) | 2 (15) | 5 (13) |
Divorced | 2 (14) | 0 (0) | 0 (0) | 2 (5) |
Widowed | 0 (0) | 1 (8) | 0 (0) | 1 (3) |
Age; mean (range) | 53.1 | 52.5 | 46.4 | 50.7 |
(22–77) | (23–82) | (22–71) | (22–82) | |
Highest level of education; n (%) | ||||
High school/technical (or lower) | 5 (36) | 4 (33) | 5 (38) | 14 (36) |
College degree | 7 (50) | 3 (25) | 6 (46) | 16 (41) |
Graduate (or higher) | 2 (14) | 5 (42) | 2 (15) | 9 (23) |
Employment status; n (%) | ||||
Not working for pay | 7 (50) | 5 (42) | 4 (31) | 16 (41) |
Full time for pay | 4 (29) | 7 (58) | 5 (38) | 16 (41) |
Part time for pay | 2 (14) | 0 (0) | 4 (31) | 6 (15) |
Student | 1 (7) | 0 (0) | 0 (0) | 1 (3) |
Age (years) at GHD diagnosis; mean (range) | 42.0 | 38.9 | 38.0 | 39.7 |
(8–63) | (4–71) | (10–61) | (4–71) | |
Cause of AGHD; n (%) | ||||
Pituitary disease/tumor | 12 (86) | 8 (67) | 4 (31) | 24 (62) |
Head trauma | 0 (0) | 0 (0) | 2 (15) | 2 (5) |
Short stature | 1 (7) | 0 (0) | 1 (8) | 2 (5) |
Hypopituitarism | 0 (0) | 1 (8) | 1 (8) | 2 (5) |
Acromegaly; removal of pituitary gland | 0 (0) | 1 (8) | 1 (8) | 2 (5) |
Brain tumor | 0 (0) | 1 (8) | 0 (0) | 1 (3) |
Unknown | 1 (7) | 1 (8) | 4 (31) | 6 (15) |
Currently on GH treatment; n (%) | ||||
Yes | 13 (93) | 12 (100) | 9 (69) | 34 (87) |
No | 1 (7) | 0 (0) | 4 (31) | 5 (13) |
Age (years) first took GH treatment; mean (range) | 45.7a | 44.3 | 38.9b | 43.0c |
(8–63) | (5–71) | (11–61) | (5–71) | |
Number other prescription meds currently taking; mean (range) | 5.0a | 3.9 | 3.4 | 4.1 |
(1–15) | (1–7) | (0–7) | (0–15) | |
Total AGHDA d score per country; mean (range) e | 7.9 | 9.8 | 11.5 | 9.7 |
(0–20) | (0–22) | (0–23) | (0–23) | |
Number co-morbid conditions; mean (range) | 3.4 | 2.2 | 2.6 | 2.8 |
(1–7) | (0–4) | (0–8) | (0–8) |